NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”). BVS and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina and registered at 23-cv-00032, is on behalf of a class consisting of all persons and entities other than defendants who were purchased or otherwise acquired have: (a) Bioventus Class A Common Shares pursuant to and/or traceable to the offering documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 11, 2021 (the “IPO” or the “Offering “) were issued; and/or (b) Bioventus Securities between February 11, 2021 and November 21, 2022, both dates inclusive (the “Collection Period”). Plaintiff is pursuing claims against defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.

If you are a shareholder who purchased or otherwise acquired Bioventus Class A common stock pursuant to and/or traceable to the offering materials relating to the Company’s IPO or Bioventus securities during the Class Period, you have until March 13, 2023 to ask the court to appoint you as lead plaintiff for the class. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Individuals inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Bioventus is a medical technology company focused on the development and commercialization of clinical treatments to engage and enhance the body’s natural healing process.

On January 20, 2021, Bioventus filed a registration statement on Form S-1 with the SEC in connection with the IPO, which…